Johnson & Johnson is negotiating a deal to acquire Swiss biotechnology company Actelion Ltd. that would separate its commercialized portfolio from its research and development assets, Reuters reports, citing people familiar with the matter.
The deal structure would allow J&J to acquire Actelion with a cash offer in the region of US$260 per share, a little more than what it had offered when it walked away from negotiations earlier this month, the news agency said.
It also would allow Actelion shareholders to benefit financially from Actelion’s R&D pipeline, the sourcessaid.
Under the deal being discussed, Actelion’s R&D pipeline would be placed in a new publicly traded company.
The exact ownership of the new company, and whether Actelion chief executive Jean-Paul Clozel would head it, are among the details still being negotiated, the sources told Reuters.
A deal could be finalized by late January, they said, cautioning that negotiations could still end unsuccessfully.
J&J and Actelion declined to comment.
Actelion said last week it had entered into exclusive talks with J&J about a strategic transaction.
J&J had pulled out of negotiations with Actelion over price disagreements earlier this month, temporarily allowing France’s Sanofi SA to engage in one-on-one acquisition talks with Actelion.
– Contact us at [email protected]